Perspective Therapeutics (AAJ0) Stock Overview
A radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AAJ0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Perspective Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.36 |
| 52 Week High | US$4.92 |
| 52 Week Low | US$1.66 |
| Beta | 1.8 |
| 1 Month Change | -12.02% |
| 3 Month Change | -4.77% |
| 1 Year Change | -12.74% |
| 3 Year Change | -11.43% |
| 5 Year Change | -56.37% |
| Change since IPO | -82.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| AAJ0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.6% | 1.6% | -1.1% |
| 1Y | -12.7% | -0.2% | 3.3% |
Return vs Industry: AAJ0 underperformed the German Biotechs industry which returned -4.5% over the past year.
Return vs Market: AAJ0 underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| AAJ0 volatility | |
|---|---|
| AAJ0 Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: AAJ0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AAJ0's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 165 | Thijs Spoor | www.perspectivetherapeutics.com |
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.
Perspective Therapeutics, Inc. Fundamentals Summary
| AAJ0 fundamental statistics | |
|---|---|
| Market cap | €286.22m |
| Earnings (TTM) | -€101.54m |
| Revenue (TTM) | €356.08k |
Is AAJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAJ0 income statement (TTM) | |
|---|---|
| Revenue | US$409.00k |
| Cost of Revenue | US$96.18m |
| Gross Profit | -US$95.77m |
| Other Expenses | US$20.86m |
| Earnings | -US$116.63m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | -23,415.65% |
| Net Profit Margin | -28,516.14% |
| Debt/Equity Ratio | 0.5% |
How did AAJ0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/18 13:50 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Perspective Therapeutics, Inc. is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| David Lebowitz | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |